Archives

A Targeted Approach for Immunoglobulin-A Nephropathy
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
A Targeted Approach for Immunoglobulin-A Nephropathy
Background
The majority of patients with IgA nephropathy develop end stage kidney disease (ESKD) within their lifetime.1,2 Despite supportive care, 78% of patients continue to have signs and symptoms, including proteinuria and hematuria, increasing their risk of progression to kidney failure.3 Most current treatments aim to treat the clinical manifestations of CKD, not the underlying cause of IgA nephropathy.1,3
Why Attend This Webinar?
Dr. Srinivasan will discuss the four hit pathogenic process of IgA nephropathy, including the role of galactose deficient immunoglobulin-A1 (Gd-IgA1) and A-proliferation inducing ligand (APRIL). Additional pathways in the disease process will be described and a targeted treatment approach will be presented.
What You Will Learn
- The 4-hit process of IgA nephropathy
- The pivotal role of APRIL in the immune process of IgA nephropathy
- How to address multiple aspects of IgA nephropathy utilizing a targeted management approach
References
- Pitcher D, et al. Clin J Am Soc Nephrol. 2023;18(6):727-738.
- Wong K, et al. Lancet. 2024;403(10433):1279-1289.
- Lafayette R, et al. Poster. International Symposium on IgA Nephropathy. 2023 (poster P-51).
Speaker

Vinay Srinivasan, MD
He completed medical school at the University of Kentucky, Internal Medicine residency at the University of Maryland, Nephrology fellowship and sub-fellowship in Glomerular Disease and Onconephrology both at the University of Pennsylvania. Dr. Srinivasan also earned an MBA from George Washington University.
In his current position, Dr. Srinivasan sees patients with glomerular diseases and cancer related kidney disease. He is involved in medical student education and serves as a primary advisor to M1-M4 students at CMSRU. He serves as a core faculty for the Nephrology fellowship program and focuses on teaching GN and Onconephrology related topics to residents and fellows. Dr. Srinivasan also serves as an investigator for glomerular disease related clinical trials at Cooper University Hospital.
Moderator

Kelly Reed, PhD
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Kelly Reed, PhD, joined Otsuka in 2012 and is currently a Senior Medical Science Liaison on our Nephrology East Team. Dr Reed has collaborated with several national professional organizations and healthcare systems providing educational presentations on hyponatremia and Autosomal Dominant Polycystic Kidney Disease (ADPKD). She has been a leader in resource development for the MSL team, co-led the nephrology MSL new hire training program during expansion and served as a mentor to several MSL new hires. Dr Reed earned her doctorate from Virginia Commonwealth University in Richmond, Virginia and completed her clinical internship at the Mailman Center for Child Development in Miami, Florida, followed by a two year fellowship at Cincinnati Children’s Hospital Medical Center.
Vinay Srinivasan is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Kelly Reed is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.